Synergy Pharmaceuticals (SGYP) Rating Reiterated by Oppenheimer

Synergy Pharmaceuticals (NASDAQ:SGYP)‘s stock had its “hold” rating reiterated by research analysts at Oppenheimer in a note issued to investors on Thursday.

SGYP has been the topic of a number of other reports. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Synergy Pharmaceuticals in a research note on Thursday, February 1st. BidaskClub raised shares of Synergy Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, February 14th. Cantor Fitzgerald reissued a “buy” rating and issued a $10.00 target price on shares of Synergy Pharmaceuticals in a research note on Thursday, January 25th. Zacks Investment Research raised shares of Synergy Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 target price on the stock in a research note on Friday, February 16th. Finally, Citigroup lowered shares of Synergy Pharmaceuticals to a “market perform” rating in a research note on Friday, January 5th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $8.08.

How to Become a New Pot Stock Millionaire

Synergy Pharmaceuticals stock opened at $1.86 on Thursday. The firm has a market cap of $488.39, a PE ratio of -1.84 and a beta of 1.26. Synergy Pharmaceuticals has a 12 month low of $1.68 and a 12 month high of $4.86. The company has a quick ratio of 3.88, a current ratio of 4.33 and a debt-to-equity ratio of -21.05.

Synergy Pharmaceuticals (NASDAQ:SGYP) last issued its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.03. The firm had revenue of $9.40 million for the quarter, compared to analyst estimates of $7.12 million. Synergy Pharmaceuticals had a negative net margin of 1,333.76% and a negative return on equity of 652.66%. Synergy Pharmaceuticals’s quarterly revenue was up 840.0% compared to the same quarter last year. equities analysts anticipate that Synergy Pharmaceuticals will post -0.52 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. increased its holdings in shares of Synergy Pharmaceuticals by 8.7% during the 4th quarter. BlackRock Inc. now owns 21,998,125 shares of the biopharmaceutical company’s stock worth $49,056,000 after buying an additional 1,761,725 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Synergy Pharmaceuticals by 71.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,405,377 shares of the biopharmaceutical company’s stock worth $8,820,000 after buying an additional 1,417,177 shares during the last quarter. Alyeska Investment Group L.P. increased its holdings in shares of Synergy Pharmaceuticals by 42.0% during the 3rd quarter. Alyeska Investment Group L.P. now owns 2,355,681 shares of the biopharmaceutical company’s stock worth $6,831,000 after buying an additional 696,911 shares during the last quarter. OxFORD Asset Management LLP increased its holdings in shares of Synergy Pharmaceuticals by 42.5% during the 3rd quarter. OxFORD Asset Management LLP now owns 2,040,297 shares of the biopharmaceutical company’s stock worth $5,784,000 after buying an additional 608,402 shares during the last quarter. Finally, Hikari Power Ltd increased its holdings in shares of Synergy Pharmaceuticals by 26.7% during the 4th quarter. Hikari Power Ltd now owns 1,900,000 shares of the biopharmaceutical company’s stock worth $4,237,000 after buying an additional 400,000 shares during the last quarter. Institutional investors and hedge funds own 53.08% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3294437/synergy-pharmaceuticals-sgyp-rating-reiterated-by-oppenheimer.html.

Synergy Pharmaceuticals Company Profile

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Analyst Recommendations for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

QCR  Stock Rating Upgraded by BidaskClub
QCR Stock Rating Upgraded by BidaskClub
NovoCure  Raised to Buy at BidaskClub
NovoCure Raised to Buy at BidaskClub
Kulicke and Soffa Industries  Downgraded by BidaskClub
Kulicke and Soffa Industries Downgraded by BidaskClub
ICF  Raised to Strong-Buy at BidaskClub
ICF Raised to Strong-Buy at BidaskClub
Anadarko Petroleum  Set to Announce Quarterly Earnings on Tuesday
Anadarko Petroleum Set to Announce Quarterly Earnings on Tuesday
Carlyle Group  to Release Earnings on Tuesday
Carlyle Group to Release Earnings on Tuesday


© 2006-2018 Ticker Report. Google+.